secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001628280-24-009006
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma reports 2023 net loss of $6.3M; revenue $40M; Caldolor labeling expanded to infants
--------------------------------------------------------------------------------

- Net loss $6.3M for 2023, includes $3.3M non-cash charge on product discontinuation; adjusted earnings $2.4M ($0.17/share).
- Revenue $40M from four brands: Kristalose $16M, Vibativ $8.8M, Sancuso $8.1M, Caldolor $4.3M.
- FDA approved expanded Caldolor labeling for infants 3-6 months; only non-opioid injectable for pain/fever in that age group.
- NOPAIN Act expected to provide favorable CMS reimbursement for Caldolor starting 2025; company submitted request.
- Ifetroban Phase II trials ongoing for DMD, scleroderma, IPF; FDA grants >$1M; oral capsule study initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/0001628280-24-009006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/cpix-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-009006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer